APEMARS presale don reach 3.8B+ tokens — Stage 3 dey live; Plenty upside but presale risk high
APEMARS (APRZ) don rush presale fast: Stages 1–2 don sold out and the project talk say dem don sell pass 3.8 billion tokens, get 350+ holders and don raise about $79,347. As of 13 January 2026, dem enter Stage 3 (“Operation Banana Boost”) at $0.00002448 per token (Stage 2 price bin $0.00002066). The project dey advertise planned listing price of $0.0055, wey mean theoretical upside of about ~22,367% from the current Stage 3 price (Stage 2 implied ~26,520% from im price). APEMARS dey push staking and referral rewards as token utilities to make people hold and grow. The coverage dey compare this high‑upside, time‑sensitive presale to established Layer‑1 networks like Solana (SOL) and Sui (SUI), noting Solana market cap (~$79–80B), price (~$140–$142) and big daily volume, and Sui smaller but growing metrics and TVL. Both pieces stress say the article na promotional and no be investment advice. Key trading takeaways: the presale fit give extreme theoretical ROI if the token list at the advertised price, but presales get higher execution, liquidity and regulatory risk; allocations dey time‑sensitive and fit dilute a lot at listing.
Bullish
Di tori news dey bullish for APRZ price prospects for short term because sellout momentum for early stages, high advertised listing price and marketing of staking/referral mechanics fit drive demand and speculative buying during presale and immediate listing. When stages sell quick and FOMO start, e dey concentrate buying pressure on the token, give short-term upward bias compared to if interest weak. But this bullish tag na only for possible price direction relative to the token; e no consider chance say dem go reach the advertised listing price or whether price go stable after listing. Big caveats reduce confidence: presales heavy risk — the listed price fit no show, initial liquidity fit thin or dem fit lock/vest plenty, big token allocations to founders/team or referral payouts fit cause immediate dilution, and regulatory or execution failures common. For traders: short-term trades fit benefit from momentum if token list and liquidity dey, but risk management essential (small position sizing, stop-losses, know about lockups and tokenomics). Long-term bullishness uncertain and depend on execution, real utility/adoption, and token distribution; without clear fundamentals, long-term outlook remain highly speculative.